Entrada Therapeutics (TRDA) Non-Current Assets (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Non-Current Assets of $68.6 million for Q1 2026, down 17.58% year-over-year from $83.3 million in Q1 2025, and down 3.49% quarter-over-quarter from $71.1 million in Q4 2025.
Entrada Therapeutics (TRDA) Non-Current Assets (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Non-Current Assets history runs 7 years deep, the most recent figure standing at $68.6 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 17.58% year-over-year to $68.6 million; the TTM figure through Mar 2026 stood at $294.0 million (down 16.28% YoY), while the FY2025 annual figure was $71.1 million, down 17.57% from the prior year.
- Non-Current Assets for Q1 2026 stood at $68.6 million, down from $71.1 million in the prior quarter.
- The five-year high for Non-Current Assets was $103.8 million in Q2 2023, with the low at $39.7 million in Q3 2022.
- The 5-year median for Non-Current Assets is $79.6 million (2025), against an average of $73.9 million.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets jumped 491.35% in 2022, then decreased 17.58% in 2026.
- Entrada Therapeutics' Non-Current Assets stood at $42.2 million in 2022, then soared by 135.7% to $99.4 million in 2023, then decreased by 13.22% to $86.3 million in 2024, then fell by 17.57% to $71.1 million in 2025, then slipped by 3.49% to $68.6 million in 2026.
- Business Quant data shows TRDA's Non-Current Assets at $68.6 million in Q1 2026, $71.1 million in Q4 2025, and $74.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | 66.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 66.17 Mn |
| Mar 31, 2026 | 68.65 Mn |
| Dec 31, 2025 | 71.13 Mn |
| Sep 30, 2025 | 74.64 Mn |
| Jun 30, 2025 | 79.64 Mn |
| Mar 31, 2025 | 83.29 Mn |
| Dec 31, 2024 | 86.28 Mn |
| Sep 30, 2024 | 89.26 Mn |
| Jun 30, 2024 | 92.43 Mn |
| Mar 31, 2024 | 96.67 Mn |
| Dec 31, 2023 | 99.42 Mn |
| Sep 30, 2023 | 101.99 Mn |
| Jun 30, 2023 | 103.79 Mn |
| Mar 31, 2023 | 41.43 Mn |
| Dec 31, 2022 | 42.18 Mn |
| Sep 30, 2022 | 39.73 Mn |
| Jun 30, 2022 | 42.01 Mn |
| Mar 31, 2022 | 43.99 Mn |
| Dec 31, 2021 | 7.13 Mn |
| Sep 30, 2021 | 8.87 Mn |